STI-6643

N/A

Report date: 2024/11/15 11:33:26

Base Information

Drug NameSTI-6643
Drug Alias NameSTI-6643
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCluster of differentiation 47 inhibitorsT lymphocytes stimulants
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A